Antibodies to variant surface antigens of plasmodium falciparum-infected erythrocytes are associated with protection from treatment failure and the development of anemia in pregnancy

Journal of Infectious Diseases

Volumn 200, Issue 2, 2009, Pages 299-306

  Feng, Gaoqian ^a   Aitken, Elizabeth ^a   Yosaatmadja, Francisca ^a   Kalilani, Linda ^d   Meshnick, Steven R ^e   Jaworowski, Anthony ^b,c   Simpson, Julie A ^a   Rogerson, Stephen J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BURNET INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MALAWI   (Malawi)

^e IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ARTESUNATE; AZITHROMYCIN; FANSIDAR; IMMUNOGLOBULIN G; VARIANT SURFACE GLYCOPROTEIN;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNITY; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALAWI; MONOCYTE; OPSONIZATION; PARASITEMIA; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFECTION; SERUM; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANEMIA; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; ANTIMALARIALS; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; MALARIA, FALCIPARUM; MALAWI; MEMBRANE GLYCOPROTEINS; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; YOUNG ADULT;

EID: 67650665318     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/599841     Document Type: Article

References (41)

1. World Health Organization. World malaria report 2008. Geneva: World Health Organization, 2008.
2. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007; 7:93-104.
3. Walter PR, Garin Y, Blot P. Placental pathologic changes in malaria: a histologic and ultrastructural study. Am J Pathol 1982; 109:330-42.
4. Salanti A, Staalsoe T, Lavstsen T, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 2003; 49:179-91.
5. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE. Maternal antibodies block malaria. Nature 1998; 395:851-2.
6. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis 2007; 7:105-17.
7. Maubert B, Fievet N, Tami G, Cot M, Boudin C, Deloron P. Development of antibodies against chondroitin sulfate A-adherent Plasmodium falciparum in pregnant women. Infect Immun 1999;67:5367-71.
8. Ricke CH, Staalsoe T, Koram K, et al. Plasma antibodies from malariaexposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A. J Immunol 2000; 165:3309-16.
9. Duffy PE, Fried M. Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. Infect Immun 2003;71: 6620-3.
10. Staalsoe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K, Hviid L. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 2004; 363:283-9.
11. Costa FT, Avril M, Nogueira PA, Gysin J. Cytoadhesion of Plasmodium falciparum-infected erythrocytes and the infected placenta: a two-way pathway. Braz J Med Biol Res 2006; 39:1525-36.
12. Keen J, Serghides L, Ayi K, et al. HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. PLoS Med 2007; 4:e181.
13. Tebo AE, Kremsner PG, Luty AJ. Fcgamma receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro. Clin Exp Immunol 2002; 130:300-6.
14. Turrini F, Ginsburg H, Bussolino F, Pescarmona GP, Serra MV, Arese P. Phagocytosis of Plasmodium falciparum-infected human red blood cells by human monocytes: involvement of immune and nonimmune determinants and dependence on parasite developmental stage. Blood 1992; 80:801-8.
15. Djimde A, Doumbo OK, Steketee RW, Plowe CV. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 2001; 358:890-1.
16. Robert V, Roeffen W, Brasseur P, Aribot G, Verhave JP, Roussilhon C. Anti-NANP antibody and treatment efficacy in patients with acute uncomplicated falciparum malaria attacks. Parasite Immunol 2000;22: 589-93.
17. Mayxay M, Chotivanich K, Pukrittayakamee S, Newton P, Looareesuwan S, White NJ. Contribution of humoral immunity to the therapeutic response in falciparum malaria. Am J Trop Med Hyg 2001;65: 918-23.
18. Mawili-Mboumba DP, Borrmann S, Cavanagh DR, et al. Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria. J Infect Dis 2003; 187:1137-41.
19. Pinder M, Sutherland CJ, Sisay-Joof F, et al. Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children. Infect Immun 2006; 74:2887-93.
20. Aubouy A, Migot-Nabias F, Deloron P. Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyterelated genetic factors in Plasmodium falciparum malaria. Infect Genet Evol 2007;7:147-54.
21. Enevold A, Nkya WM, Theisen M, et al. Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malar J 2007; 6:153.
22. Plowe CV, Kublin JG, Dzinjalamala FK, et al. Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. BMJ 2004; 328:545.
23. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 2007; 297:2603-16.
24. Kalilani L, Mofólo I, Chaponda M, et al. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS ONE 2007; 2:e1166.
25. Kwiek JJ, Alker AP, Wenink EC, Chaponda M, Kalilani LV, Meshnick SR. Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections. Antimicrob Agents Chemother 2007;51:521-7.
26. Goodyer ID, Johnson J, Eisenthal R, Hayes DJ. Purification of maturestage Plasmodium falciparum by gelatine flotation. Ann Trop Med Parasitol 1994; 88:209-11.
27. Gebran SJ, Romano EL, Pons HA, Cariani L, Soyano AN. A modified colorimetric method for the measurement of phagocytosis and antibody-dependent cell cytotoxicity using 2,7-diaminofluorene. J Immunol Methods 1992; 151:255-60.
28. Elliott SR, Brennan AK, Beeson JG, et al. Placental malaria induces variant-specific antibodies of the cytophilic subtypes immunoglobulin G1 (IgG1) and IgG3 that correlate with adhesion inhibitory activity. Infect Immun 2005; 73:5903-7.
29. Megnekou R, Staalsoe T, Taylor DW, Leke R, Hviid L. Effects of pregnancy and intensity of Plasmodium falciparum transmission on immunoglobulin G subclass responses to variant surface antigens. Infect Immun 2005;73:4112-8.
30. Kalanda GC, Hill J, Verhoeff FH, Brabin BJ. Comparative efficacy of chloroquine and sulphadoxine-pyrimethamine in pregnant women and children: a meta-analysis. Trop Med Int Health 2006; 11:569-77.
31. Tagbor H, Bruce J, Ord R, et al. Comparison of the therapeutic efficacy of chloroquine and sulphadoxine-pyremethamine in children and pregnant women. Trop Med Int Health 2007; 12:1288-97.
32. Mount AM, Mwapasa V, Elliott SR, et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 2004; 363:1860-7.
33. Jaworowski A, Fernandes LA, Yosaatmadja F, et al. Relationship between human immunodeficiency virus type 1 coinfection, anemia, and levels and function of antibodies to variant surface antigens in pregnancy-associated malaria. Clin Vaccine Immunol 2009; 16:312-9.
34. Hviid L. Development of vaccines against Plasmodium falciparum malaria: taking lessons from naturally acquired protective immunity. Microbes Infect 2007;9:772-6.
35. Tippett E, Fernandes LA, Rogerson SJ, Jaworowski A. A novel flow cytometric phagocytosis assay of malaria-infected erythrocytes. J Immunol Methods 2007; 325:42-50.
36. Struik SS, Omer FM, Artavanis-Tsakonas K, Riley EM. Uninfected erythrocytes inhibit Plasmodium falciparum-induced cellular immune responses in whole-blood assays. Blood 2004; 103:3084-92.
37. Nosten F, Rogerson SJ, Beeson JG, McGready R, Mutabingwa TK, Brabin B. Malaria in pregnancy and the endemicity spectrum: what can we learn? Trends Parasitol 2004; 20:425-32.
38. Rogerson SJ, van den Broek NR, Chaluluka E, Qongwane C, Mhango CG, Molyneux ME. Malaria and anemia in antenatal women in Blantyre, Malawi: a twelve-month survey. Am J Trop Med Hyg 2000;62: 335-40.
39. Menendez C, Ordi J, Ismail MR, et al. The impact of placental malaria on gestational age and birth weight. J Infect Dis 2000; 181:1740-5.
40. Verhoeff FH, Brabin BJ, Hart CA, Chimsuku L, Kazembe P, Broadhead RL. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop Med Int Health 1999; 4:5-12.
41. Steketee RW, Wirima JJ, Bioland PB, et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996;55:42-9.